Acquired by NovaQuest Capital Management in January 2018.

Developer of therapies based on metalloenzyme chemistry and biology platform. The company focuses on the discovery, development, and commercialization of novel therapeutic agents that target metalloenzymes or interfere with the cell's ability to effectively utilize critical metal ions including zinc and iron for invasive and hospital-based fungal infections, cancer, cardiovascular and orphan diseases, enabling the patients and clinicians to provide greater selectivity and safety as well as improved potency compared to currently available therapeutics.